pitavastatin / Generic mfg. - LARVOL DELTA

Risk of new-onset diabetes across individual statins in secondary prevention: results from the Korean national health insurance service cohort. (PubMed, Front Cardiovasc Med) - "In the moderate-intensity group, rosuvastatin (adjusted HR 1.07, 95% CI 1.01-1.14), pravastatin (HR 1.19, 95% CI 1.02-1.38), and simvastatin (HR 1.15, 95% CI 1.06-1.20) were associated with higher NODM risk compared with atorvastatin, while fluvastatin and pitavastatin showed no significant differences. In this nationwide secondary prevention cohort, the risk of NODM differed across individual statins despite comparable cardiovascular outcomes. These findings suggest that the diabetogenic effect of statins may be agent-specific rather than a uniform class effect, highlighting the importance of individualized statin selection balancing metabolic and cardiovascular benefits."

Journal • Reimbursement • US reimbursement • Atherosclerosis • Cardiovascular • CNS Disorders • Diabetes • Metabolic Disorders

PROBUCOL HALVES ALL-CAUSE DEMENTIA RISK: EVIDENCE FROM A NATIONWIDE COHORT (ADPD 2026) - P2 | "Protective associations were consistent across individual statins, most pronounced versus pravastatin (aOR = 0.31, 95% CI: 0.24–0.38) and pitavastatin (aOR = 0.30, 95% CI: 0.24–0.38). Conclusions Probucol use was associated with significant lower odds of dementia, with robust effects across statin comparators. These findings highlight the translational potential of targeting peripheral amyloid–capillary interactions. Confirmation in the ongoing Probucol in Alzheimer's Study (ACTRN12621000726853) could provide a compelling rationale for scalable and cost-effective adoption of probucol in dementia prevention and treatment."

Alzheimer's Disease • CNS Disorders • Dementia • Inflammation

BP45863: A study investigating the safety of RO7795074, a new compound that may potentially be used in the treatment of type 1 diabetes, and the effect of RO7795074 on how the body processes pitavastatin (clinicaltrialsregister.eu) - P1 | N=32 | Active, not recruiting | Sponsor: Genentech Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders • Obesity • Type 1 Diabetes Mellitus

LDB1-dependent enhancer connectivity constrains a metabolic synthetic lethality in T-cell acute lymphoblastic leukemia (AACR 2026) - "Using both LDB1 degron and knockout models, we observed that LDB1 loss sensitizes leukemic cells to rosuvastatin and pitavastatin by 2-5-fold...Furthermore, statin sensitization was rescued by spike-in of mevalonate or geranylgeranyl pyrophosphate, confirming that this phenotype is driven by altered cholesterol metabolism.Together, our study illustrates a paradigm by which LDB1 loss enables illegitimate spatial connections of enhancers with cholesterol biosynthetic gene promoters. This, in turn, creates a new metabolic addiction in leukemic cells, which may be targeted with statins."

Synthetic lethality • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • DUSP6 • HMGCS1 • LMO2 • MVD • MYCN • STAT4

ATORVASTATIN METABOLITES WITH ANTIOXIDANT ACTIONS LIMIT RAPID OXIDATION OF LIPOPROTEIN(A)-ENRICHED PLASMA MORE EFFECTIVELY THAN OTHER STATINS (ACC 2026) - "We compared the metabolites' effects to other active statins - pitavastatin, rosuvastatin, pravastatin, and simvastatin - on oxidation in plasma samples enriched with Lp(a) and other atherogenic lipoproteins, including small dense LDL (sdLDL). Active metabolites of atorvastatin inhibited oxidation of Lp(a), sdLDL, and LDL enriched plasma compared to other widely used statins as well as in cholesterol-enriched lipid membranes, likely due to free radical scavenging. The potent antioxidant actions of atorvastatin active metabolites may reduce atherogenicity of Lp(a) in patients independent of the production of this atherogenic particle."

Atherosclerosis • Cardiovascular • APOB

Statin Induced New-onset Diabetes Mellitus - A Narrative Review. (PubMed, J Community Hosp Intern Med Perspect) - "High-intensity statins like atorvastatin and rosuvastatin carry a greater risk compared to agents such as pravastatin or pitavastatin. Despite the diabetes risk associated with statins, their well-established cardiovascular benefits generally outweigh this concern. This review discusses the current evidence on the association between statin use and NODM, explores potential biological mechanisms, compares the diabetogenic effects of different statins, assess the impact of statin dose and intensity, and outlines implications for clinical practice."

Journal • Review • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Atorvastatin suppresses HIV/antiretroviral drug-induced cardiac fibrosis and dysfunction in mice by blocking platelet TGFβ1 signaling. (PubMed, JCI Insight) - "In the REPRIEVE trial, pitavastatin reduces atherosclerotic CVD risk to a magnitude inconsistent with pitavastatin's impact solely on LDL-cholesterol and inflammation...ART drugs used in REPRIEVE, including a nucleoside/nucleotide, integrase inhibitor-based regimen (tenofovir (TDF), emtricitabine (FTC), and dolutegravir (DTG)), and the protease inhibitors ritonavir (RTV) and darunavir (DRV), and the impact of atorvastatin, were examined in two HIV mouse models: transgenic HIV-Tg26 mice and HIV-PDX mice engrafted with T cells isolated from PWH...Administration of TDF-FTC-DTG or RTV, but not DRV, resulted in a further ~2-fold increase in fibrosis (p<0.01)...Our results indicate that certain ART regimens accelerate HIV-associated CVD characterized by HFpEF via platelet TGFβ1-dependent processes, which were mitigated by atorvastatin. We postulate that our findings provide a potential mechanism for the pleiotropic effects of statins in HIV/ART-linked CVD which could be..."

Journal • Preclinical • Atherosclerosis • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation

TRIal of STatin Therapy Effect on Androgen Status and Erectile functioN in Men (clinicaltrials.gov) - P2 | N=150 | Recruiting | Sponsor: Lomonosov Moscow State University Medical Research and Educational Center

New P2 trial • Atherosclerosis • Cardiovascular • Erectile Dysfunction

EBM BLS: Pitavastatin Reduces Cardiovascular Events in People Living with HIV With Low-to-Moderate Cardiovascular Risk. (PubMed, J Gen Intern Med) - No abstract available

Journal • Cardiovascular • Human Immunodeficiency Virus • Infectious Disease

A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Jun 2026 ➔ Dec 2026 | Trial primary completion date: Jun 2026 ➔ Dec 2026

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

Efficacy and Safety of Pitavastatin/Ezetimibe After Switching From Statin Monotherapy to Pitavastatin/Ezetimibe in Patients With Hypercholesterolemia (clinicaltrials.gov) - P=N/A | N=6927 | Completed | Sponsor: JW Pharmaceutical

Monotherapy • New trial • Dyslipidemia • Metabolic Disorders

Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides (clinicaltrials.gov) - P4 | N=88 | Active, not recruiting | Sponsor: JW Pharmaceutical

New P4 trial • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders

BP45863: A study investigating the safety of RO7795074, a new compound that may potentially be used in the treatment of type 1 diabetes, and the effect of RO7795074 on how the body processes pitavastatin (clinicaltrialsregister.eu) - P1 | N=32 | Recruiting | Sponsor: Genentech Inc.

New P1 trial • Diabetes • Metabolic Disorders • Obesity • Type 1 Diabetes Mellitus

Three-drug combination therapy to prevent glucocorticoid-associated osteonecrosis in patients with systemic lupus erythematosus: a proof-of-concept study. (PubMed, Ther Adv Musculoskelet Dis) - "To investigate the efficacy and safety of a three-drug combination therapy consisting of clopidogrel sulfate, pitavastatin calcium hydrate, and tocopherol acetate, administered concurrently with initial glucocorticoid therapy to prevent ONFH in patients with SLE. Although the results should be regarded as preliminary and hypothesis-generating, they suggest a potential signal that warrants further investigation in adequately powered randomized controlled trials. Clinical trial for the control of osteonecrosis of the femoral head secondary to the initial corticosteroid treatment in patients with systemic lupus erythematosus (UMIN000008230; https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009636)."

Journal • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Targeting HIF-2α in Colorectal Cancer Reveals a Cholesterol Biosynthesis-Dependent Ferroptotic Vulnerability. (PubMed, bioRxiv) - "Targeting this pathway with clinically approved statins (atorvastatin, pitavastatin, simvastatin) synergized with PT2385 to suppress CRC cell growth, reduce colony formation, and enhance cell death...These effects are fully reversed by the ferroptosis inhibitor liproxstatin-1...In vivo, co-administration of PT2385 and atorvastatin significantly reduced tumor growth and increased ferroptotic cell death in xenografts, confirming the mechanistic link. Collectively, these findings uncover a metabolic vulnerability of CRC to dual HIF-2α and cholesterol biosynthesis inhibition, supporting a clinically actionable strategy that leverages safe, FDA-approved statins to potentiate HIF-2α-targeted therapy."

Journal • Colorectal Cancer • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • EPAS1

A Two Birds with One Stone Strategy: Sialic Acid-Modified Pitavastatin Liposomes for Combating Atherosclerosis and Tumors. (PubMed, Mol Pharm) - "Notably, PIT-SAL additionally exhibited antitumor potential by effectively reducing tumoral cholesterol accumulation while enhancing T-cell infiltration. Collectively, our preliminary findings highlight the great translational potential of PIT-SAL as a targeted therapy for both AS and tumors, offering a potential breakthrough in managing these interconnected diseases."

Journal • Atherosclerosis • Cardiovascular • Oncology

The Effect of Ecopipam on the Pharmacokinetics of Concomitant Medications. (PubMed, Clin Transl Sci) - "Cohort 3 received an oral solution containing microdoses of dabigatran (P-gp), pitavastatin (OATP1B1), rosuvastatin (BCRP, OATP, and P-gp), atorvastatin (BCRP, OATP, P-gp, and CYP3A4), and midazolam...Steady-state ecopipam administration increased dextromethorphan exposure (> 100-fold); decreased the AUCinf of midazolam, omeprazole, and dabigatran by 44.2%, 44.1%, and 37.9%, respectively; and decreased unconjugated bilirubin (UGT1A1) by 19.5%...There were no changes in caffeine, bupropion, or pitavastatin exposure. Ecopipam is a strong inhibitor of CYP2D6 and weak inducer of CYP3A4, CYP2C19, P-gp, and UGT1A1. Ecopipam did not inhibit CYP3A4, CYP2C19, CYP2B6, CYP1A2, UGT1A1, P-gp, or OATP1B1 and did not induce OATP1B1 or CYP2B6."

Journal • PK/PD data • Movement Disorders • Tourette Syndrome • CYP1A2 • CYP2C19 • CYP3A4 • UGT1A1

Chemotherapy plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer: An Exploratory Phase I Trial (ChiCTR) - P=N/A | N=22 | Not yet recruiting | Sponsor: Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital

New trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Economic implications of the different statin prescribing patterns in Central Portugal: a longitudinal analysis. (PubMed, J Pharm Policy Pract) - "These discrepancies were associated with the percentage of pitavastatin in DDD (F = 4.604; p = 0.005), and the percentage of statins monotherapy in DDD (F = 5.201; p = 0.003)...Differences in prescribing patterns resulted in very different proportions of patients treated and expenses associated with the consumption of these lipid-lowering agents. Further analysis should be carried out to understand the financial implications of prescribing new (patent-protected) medicines in Portugal."

Journal

CPPGPTCLC: Chemotherapy Plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=22 | Not yet recruiting | Sponsor: Chang Chen

New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Impact of pitavastatin on carotid plaque regression in patients with hypercholesterolemia. (PubMed, Ann Vasc Surg) - "The pitavastatin-based lipid-lowering treatment resulted in statistically significant regression of carotid atherosclerotic plaques. More research is needed to determine the effects of the observed changes on clinical outcomes."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders

Safety Comparison of Risk of Liver Dysfunction between Generic and Brand Statin Drugs Marketed in Japan: A Cohort Study Using MID-NET®. (PubMed, Ther Innov Regul Sci) - "A new user cohort design was employed in which patients prescribed one of six statins (atorvastatin, simvastatin, pitavastatin, pravastatin, fluvastatin, or rosuvastatin) in Japan between January 1, 2014 and March 31, 2022 were identified in the MID-NET® database. Results suggest that risks of liver dysfunction by generic statins are similar to those for brand drugs, facilitating our understanding about the safety of generic drugs. The aHR for atorvastatin was inconsistent between the primary and additional analyses, which suggests that the observed increased risk of generic atorvastatin may be affected by other factors and does not necessarily indicate a different safety profile between generic and brand drugs."

Journal • Hepatology • Liver Failure

Ribociclib drug-drug interaction and concomitant medication management in early and advanced breast cancer patients (SABCS 2025) - "Background: Ribociclib is approved for the treatment of HR+/HER2- advanced or metastatic breast cancer (ABC) in combination with an aromatase inhibitor or fulvestrant, and more recently, for the adjuvant treatment of HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence, with the starting dose of 600 mg in ABC and 400mg in EBC...The effect of ribociclib on rosuvastatin, pravastatin, pitavastatin, and fluvastatin is considered minor with no clinical relevance, since these statins are not sensitive CYP3A4 substrates...No clinically relevant DDI is expected for commonly used antidepressants/antipsychotics, such as citalopram, escitalopram, fluoxetine, mirtazapine, sertraline, trazodone, venlafaxine, aripiprazole, olanzapine and cariprazine, when co-administered with ribociclib 400 mg or 600 mg... No clinically relevant DDI with ribocicilib is anticipated for commonly used statins or antidepressants/antipsychotics, except simvastatin, lovastatin,..."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Baseline ECG and Cardiovascular Outcomes in People With HIV: Insights From REPRIEVE. (PubMed, J Am Heart Assoc) - "Among PWH in REPRIEVE, electrocardiographic abnormalities were common, but major electrocardiographic abnormalities were rare. Though major abnormalities were associated with increased hazard of MACEs, routine electrocardiographic screening is unlikely to improve the prediction of future cardiovascular events in this primary prevention population with low to moderate cardiovascular risk."

Journal • Atherosclerosis • Cardiovascular • Human Immunodeficiency Virus • Infectious Disease

OPTIMAR: Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART) (clinicaltrials.gov) - P3 | N=300 | Active, not recruiting | Sponsor: Kirby Institute | Recruiting ➔ Active, not recruiting

Enrollment closed • Congestive Heart Failure • Human Immunodeficiency Virus • Infectious Disease